Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COVID-19 and a Tale of Three Drugs: To Repurpose, or Not to Repurpose-That Was the Question.

Viruses·2025
Same author

Repurposing Metformin for the Treatment of Atrial Fibrillation: Current Insights.

Vascular health and risk management·2024
Same author

Metabolic heterogeneity in TNBCs: A potential determinant of therapeutic efficacy of 2-deoxyglucose and metformin combinatory therapy.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2023
Same author

Biofunctionalization of cardiovascular stents to induce endothelialization: Implications for in- stent thrombosis in diabetes.

Frontiers in pharmacology·2022
Same author

Repurposing Metformin for Vascular Disease.

Current medicinal chemistry·2022
Same author

Metformin: Is it a drug for all reasons and diseases?

Metabolism: clinical and experimental·2022

Related Experiment Video

Updated: Sep 29, 2025

Standardized and Scalable Assay to Study Perfused 3D Angiogenic Sprouting of iPSC-derived Endothelial Cells In Vitro
10:47

Standardized and Scalable Assay to Study Perfused 3D Angiogenic Sprouting of iPSC-derived Endothelial Cells In Vitro

Published on: November 6, 2019

30.7K

3D Tissue-Engineered Vascular Drug Screening Platforms: Promise and Considerations.

Isra Marei1,2, Tala Abu Samaan1, Maryam Ali Al-Quradaghi1

  • 1Department of Pharmacology, Weill Cornell Medicine-Qatar, Doha, Qatar.

Frontiers in Cardiovascular Medicine
|March 21, 2022
PubMed
Summary
This summary is machine-generated.

Developing advanced 3D tissue engineered vascular constructs from human cells is crucial for improving preclinical drug screening. This approach aims to bridge the gap between current methods and human clinical trials, enhancing drug discovery efficiency.

Keywords:
3D bioprinting3D drug screeningbioreactorspersonalizationscaffoldsself-organization and self-assemblystem cellstissue engineered blood vessels

More Related Videos

Author Spotlight: Automated Bioprinting for High-Throughput Vascular Model Fabrication
07:41

Author Spotlight: Automated Bioprinting for High-Throughput Vascular Model Fabrication

Published on: August 16, 2024

1.3K
Tissue Engineering of a Human 3D in vitro Tumor Test System
11:12

Tissue Engineering of a Human 3D in vitro Tumor Test System

Published on: August 6, 2013

21.5K

Related Experiment Videos

Last Updated: Sep 29, 2025

Standardized and Scalable Assay to Study Perfused 3D Angiogenic Sprouting of iPSC-derived Endothelial Cells In Vitro
10:47

Standardized and Scalable Assay to Study Perfused 3D Angiogenic Sprouting of iPSC-derived Endothelial Cells In Vitro

Published on: November 6, 2019

30.7K
Author Spotlight: Automated Bioprinting for High-Throughput Vascular Model Fabrication
07:41

Author Spotlight: Automated Bioprinting for High-Throughput Vascular Model Fabrication

Published on: August 16, 2024

1.3K
Tissue Engineering of a Human 3D in vitro Tumor Test System
11:12

Tissue Engineering of a Human 3D in vitro Tumor Test System

Published on: August 6, 2013

21.5K

Area of Science:

  • Biomedical Engineering
  • Cardiovascular Research
  • Drug Discovery

Background:

  • Drug approvals, especially for cardiovascular diseases, are declining due to increasing adverse effects and regulatory hurdles.
  • Current 2D cell culture models fail to replicate the complex human physiological microenvironment, leading to discrepancies in preclinical and clinical drug testing.
  • Existing 2D cell-based screening systems lack the complexity to accurately predict drug efficacy and toxicity in humans.

Purpose of the Study:

  • To highlight the limitations of current preclinical drug screening methods, particularly for cardiovascular drugs.
  • To introduce the potential of 3D tissue-engineered vascular constructs as a more physiologically relevant in vitro model.
  • To discuss critical factors for developing reliable and reproducible human cell-derived vascular constructs for drug screening.

Main Methods:

  • Review of existing literature on drug discovery, preclinical screening methods, and tissue engineering.
  • Analysis of the shortcomings of 2D cell culture and animal models in predicting human physiological responses.
  • Discussion of the principles and considerations for creating 3D vascular constructs using human cells.

Main Results:

  • Identified a significant gap between current in vitro/in vivo preclinical models and human clinical outcomes.
  • Highlighted the inability of 2D cell cultures to mimic the complex cellular microenvironment and its impact on drug response.
  • Emphasized the need for advanced in vitro models that better recapitulate human physiology.

Conclusions:

  • 3D tissue-engineered vascular constructs offer a promising solution to improve the accuracy and efficiency of preclinical drug screening.
  • Developing reliable and reproducible human cell-based vascular constructs is essential for advancing cardiovascular drug discovery.
  • This approach has the potential to reduce drug attrition rates and accelerate the development of safe and effective cardiovascular therapies.